Bausch Health Cos (NYSE:BHC) Stock Price Down 4.5% - Time to Sell?

Key Points

• Bausch Health Cos experienced a 4.5% decline in stock price, trading at $7.97, down from a previous close of $8.34.
• Analysts have upgraded the stock, with Royal Bank of Canada raising its price target from $8.50 to $10.00 and changing its rating to "sector perform."
• Insider John Paulson purchased 34.7 million shares, increasing his ownership stakes and signaling potential confidence in the company's future performance.

Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) fell 4.5% on Monday . The stock traded as low as $7.98 and last traded at $7.97. 2,517,543 shares changed hands during trading, a decline of 7% from the average session volume of 2,699,024 shares. The stock had previously closed at $8.34.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BHC shares. Royal Bank Of Canada upped their price target on Bausch Health Cos from $8.50 to $10.00 and gave the stock a "sector perform" rating in a report on Friday, May 2nd. Wall Street Zen upgraded Bausch Health Cos from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd.

Bausch Health Cos Stock Down 3.8%

The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of 30.85 and a beta of 0.41. The firm has a 50 day simple moving average of $6.38 and a 200-day simple moving average of $6.01.

Bausch Health Cos (NYSE:BHC - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The firm had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.47 billion. On average, sell-side analysts forecast that Bausch Health Cos Inc. will post 4.41 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director John Paulson bought 34,721,118 shares of the firm's stock in a transaction dated Thursday, August 14th. The stock was bought at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the transaction, the director owned 70,755,869 shares of the company's stock, valued at $636,802,821. This represents a 96.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought a total of 44,316,834 shares of company stock valued at $369,628,560 over the last quarter. Corporate insiders own 8.12% of the company's stock.

Institutional Trading of Bausch Health Cos

A number of hedge funds and other institutional investors have recently modified their holdings of BHC. Cary Street Partners Financial LLC bought a new stake in Bausch Health Cos in the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd acquired a new position in Bausch Health Cos in the 1st quarter valued at $27,000. SBI Securities Co. Ltd. grew its stake in Bausch Health Cos by 244.2% during the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after buying an additional 3,001 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company's stock valued at $51,000 after buying an additional 3,106 shares in the last quarter. Finally, Wealthquest Corp acquired a new stake in shares of Bausch Health Cos during the 1st quarter worth approximately $58,000. Institutional investors and hedge funds own 78.65% of the company's stock.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.